In conclusion, zampilimab inhibited extracellular TG2 activity both in vitro and in vivo, reducing accumulation of ECM components, slowing wound healing in human cells, and reducing fibrosis development in a cynomolgus monkey UUO model of CKD. The gene discussed is TGM2; the disease is chronic kidney disease.